Results from a big clinical trial show that adding blinatumomab (Blincyto) to the treatment of people with lymphoblastic leukemia ba'an (ALL) who are in remission, even if there are no signs of their disease, can help them live longer.
In the study, giving blinatumomab along with chemotherapy made people with cancer that had gone into remission live much longer than those who only got chemotherapy, which is the current standard treatment. Patients in the trial were not only in remission, but there was no sign of their cancer. This is called having minimum residual disease (MRD)-negative ALL.
Natiijooyinka tijaabada ayaa lagu muujiyay shirkii sannadlaha ah ee Bulshada Maraykanka ee Dhiigbaxa (ASH) ee New Orleans Diseembar 2022.
In 2018, the Food and Drug Administration (FDA) cleared blinatummab to treat people with MRD-positive ALL who were in remission but still showed signs of cancer during follow-up tests. Even though recurrences after remission are always possible, people with MRD-positive ALL have a higher chance of their cancer coming back after their first treatment than those who do not have MRD.
At the ASH meeting, the results were shown for people who did not have MRD after their first medication.
Sanadihii 3.5 ka dib markii la bilaabay daawaynta ka dib, 83% bukaanada lagu daweeyay blinatummab iyo kiimoterabiga ayaa wali nool, halka 65% kaliya ee bukaanada lagu daweeyay kemotherabi ay wali nool yihiin.
Blinatumomab waxtar u leh MRD-negative DHAMMAAN sidoo kale
B-cell ALL is the most common type of ALL in both adults and children. It is a type of kansarka dhiigga that spreads quickly and is very dangerous. Chemotherapy is the standard treatment, and it often leads to remission. However, a lot of people get sick again, even if tests done after treatment show no signs of disease.
Daawooyinka Immunotherapy waxay muujiyeen xoogaa ballanqaad ah oo ah dariiqa lagu daweyn karo kansarka ka dib marka ay soo baxdo oo ay hoos u dhigto khatarta ah inuu soo laabto.
Nooc ka mid ah immunotherapy called a bispecific T-cell engager (BiTE) is what blinatumomab is. It sticks to both T cells and cancer cells at the same time. This makes it easy for T cells to find and kill the cancer cell by bringing them closer together. The drug, which is given through an IV, has been shown to be more effective than chemotherapy at treating B-ALL that has come back in children and young adults who have already been treated for it.
Tijaabadan, oo ay wadaan Kooxda Cilmi-baadhista Kansarka ECOG-ACRIN oo gacan ka helaysa NCI, waxay bilaabatay 2013 si loo eego bal in blinatummab ay caawin karto dadka hadda laga helay B-cell ALL.
Inkasta oo 488 qof ay ka qaybqaateen tijaabada guud ahaan, natiijooyinka lagu muujiyay ASH waxay ahaayeen kaliya 224 qof ee ku jiray cafiska iyo MRD-negative ka dib hababka caadiga ah ee daaweynta kemotherabi ee bilowga ah. Bukaannada waxaa la siiyay daawayn kiimiko oo dheeraad ah marka lagu daro blinatumomab ama kaliya kiimoterabi. Kadib, maaddooyinka oo dhan waxay heleen kiimoterabi lixdii biloodba mar ilaa 2.5 sano. Dadka qaar ayaa sidoo kale lagu beeray dhuuxa lafta haddii dhakhtarkoodu u maleeyay inay ugu fiican tahay.
Ma aha oo kaliya in ku darista blinatummab ee kiimoterabiga ay wanaajisay badbaadada guud, laakiin waxay sidoo kale ka dhigtay bukaanada inay sii noolaadan wakhti dheer iyada oo aan kansarku soo laabanayn marka la barbardhigo kuwa kaliya ee qaatay kiimoterabiga.
Dr. Litzow said that none of the people who took blinatumomab had any unexpected side effects. Some of the most common side effects of blinatumomab are fever, responses to the infusion, headaches, infections, tremors, and chills.
